Blood Urea Nitrogen for Short-Term Prognosis in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction
Table 1
Baseline characteristics and medications of the study population.
Variables
Total (n = 218)
CS survivors (n = 113)
CS nonsurvivors (n = 105)
value
Age (years)
72.5 (63, 78)
66 (59, 75)
75 (69, 81)
<0.001
Male (%)
142 (65.1%)
81 (71.7%)
61 (58.1%)
0.04
BMI (kg/m2)
23.1 ± 3.0
23.6 ± 2.9
22.6 ± 3.1
0.02
Hypertension (%)
109 (50%)
57 (50.4%)
52 (49.5%)
0.89
Diabetes (%)
73 (33.5%)
35 (31.0%)
38 (36.2%)
0.42
Dyslipidemia (%)
15 (6.9%)
8 (7.1%)
7 (6.7%)
0.90
Smoking (%)
115 (52.8%)
73 (64.6%)
42 (40.0%)
<0.001
History of stroke (%)
15 (6.9%)
5 (4.4%)
10 (9.5%)
0.14
History of AF (%)
13 (6.0%)
6 (5.3%)
7 (6.7%)
0.67
Prior MI (%)
12 (5.5%)
3 (2.7%)
9 (8.6%)
0.06
SBP (mmHg)
85 (78, 93)
87 (79, 99)
85 (78, 90)
0.02
DBP (mmHg)
56 (50, 63)
57 (51, 64)
55 (48.5, 60.5)
0.17
Heart rate (bpm)
87.6 ± 28.1
84.1 ± 27.8
91.4 ± 28.0
0.06
MI localization (%)
Anterior
80 (36.7%)
39 (34.5%)
41 (39.0%)
0.49
Inferior
94 (43.1%)
53 (46.9%)
41 (39.0%)
0.24
Lateral
18 (8.3%)
7 (6.2%)
11 (10.5%)
0.25
Right ventricle
27 (12.4%)
18 (15.9%)
9 (8.6%)
0.10
Medications (%)
Aspirin
201 (92.2%)
106 (93.8%)
95 (90.5%)
0.36
Clopidogrel
114 (52.3%)
61 (54.0%)
53 (50.5%)
0.61
Ticagrelor
115 (52.8%)
68 (60.2%)
47 (44.8%)
0.02
Statins
201 (92.2%)
111 (98.2%)
90 (85.7%)
0.001
ACEI/ARB
74 (33.9%)
53 (46.9%)
21 (20.0%)
<0.001
β-blocker
123 (56.4%)
77 (68.1%)
46 (43.8%)
<0.001
Diuretics
119 (54.6%)
61 (54.0%)
58 (55.2%)
0.85
Dopamine
106 (48.6%)
45 (39.8%)
61 (58.1%)
0.007
Norepinephrine
30 (13.8%)
8 (7.1%)
22 (21.0%)
0.003
Nitrates
63 (28.9%)
34 (30.1%)
29 (27.6%)
0.69
Digitalis
28 (12.8%)
14 (12.4%)
14 (13.3%)
0.84
Data are expressed as mean ± SD, median (IQR) or number (percentage). CS: cardiogenic shock, BMI: body mass index, AF: atrial fibrillation, MI: myocardial infarction, SBP: systolic blood pressure, DBP: diastolic blood pressure, and ACEI/ARB: angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.
